Key points from article :
The founders of cellvie wondered if it were possible to replace and augment damaged mitochondria.
Have raised $5 million in Kizoo-led seed funding.
Therapeutic Mitochondria Transplantation (TMT) holds the potential of sustainably affecting mitochondria function.
Want to establish off-the-shelf mitochondria that can be frozen, then thawed for immediate use by the physician.
Looking at where therapeutic mitochondria can intersect with age-related degeneration.
Ischemia-reperfusion injury is its frontrunner indication which has a timelier endpoint than ageing.
Can then develop, longer-term, aging-related applications.
